Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma
Cancer Immunology, Immunotherapy · 2023
DOI: 10.1007/s00262-023-03434-2 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Qi Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cance…. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Neoplasms, Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: This study was funded by Suzhou Transcenta Therapeutics Co., Ltd, a wholly owned subsidiary of Transcneta Holding Limited..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Fucheng Road 52, Haidian District, Beijing, 10…
- Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Colorectal Medicine, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, C…
- Department of Medical Oncology, Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Oncology, Nantong Tumor Hospital & Affiliated Tumor Hospital of Nantong University, Nantong, China.
Förderung
- This study was funded by Suzhou Transcenta Therapeutics Co., Ltd, a wholly owned subsidiary of Transcneta Holding Limited.
Zitieren
APA
Zhang, Q., Zhang, J., Zhong, H., Yuan, Y., Yang, L., Zhang, Q., Ji, D., Gong, J., Li, J., Yao, Z., Qi, C., Wang, J., Lu, L., Shi, M., Qian, X., Shen, L., Li, J., & Hu, X. (2023). Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03434-2
Vancouver
Zhang Q, Zhang J, Zhong H, Yuan Y, Yang L, Zhang Q, et al. Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03434-2
BibTeX
@article{Zhang2023,
author = {Zhang, Qi and Zhang, Jian and Zhong, Haijun and Yuan, Ying and Yang, Lei and Zhang, Qingyuan and Ji, Dongmei and Gong, Jifang and Li, Jing and Yao, Zhenling and Qi, Chuan and Wang, Jianming and Lu, Lingmin and Shi, Michael and Qian, Xueming and Shen, Lin and Li, Jian and Hu, Xichun},
title = {Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
doi = {10.1007/s00262-023-03434-2}
}
EUVIMED